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received BVS, 4 (7.4%) of them were multiple. 3 patients received
2 scaffolds in 2 vessels while 1 patient received 2 scaffolds in the
same vessel. The mean age was 57.3  9.7 years. The location of
the lesions was LAD (32), LCx (11) and RCA (14). The length of
devices most frequently used included 18 mm (29), 28 mm (28)
and 38 mm (1). Procedural success was obtained in 53 cases. The
diameter of devices most frequently used included 2.5 mm (27),
3.0 mm (22) and 3.5 mm (9). One patient had a slow ﬂow phe-
nomenon (ﬁnal TIMI ﬂow 2). At 6-month follow-up, one late
stent thrombosis was reported in one patient 60 days after PCI
requiring re-PCI.
Conclusions: BVS implantation can be successfully performed
with a high procedural success rate and encouraging midterm
outcomes. Larger randomized trails and longer follow-up
are needed to access the potential clinical beneﬁt of BVS
versus new generation DES as these results are from a single
center.
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Objective: Aim of the study was to evaluate demographic, clinical,
angiographic proﬁle and endovascularmanagement of Takayasu's
arteritis.
Background: Takayasu's arteritis is a chronic inﬂammatory vas-
culitis affecting the aorta and its major branches. Although it is
more prevalent in Asia, the distribution of the disease is worldwide
with different vascular involvement patterns and clinical mani-
festations.
Methods: In this prospective study, a total of 50 consecutive
patientswhowere reported as having Takayasu's arteritis between
January 2010 and April 2014 were evaluated. Detailed demographic
proﬁle, clinical presentation, and angiograms of all patients were
analyzed.
Results: A total of 50 patients were analyzed during study period.
Among 50 patients, 43 (86%) were female and 7 (14%) were male.
Average age of presentation was 26.92 years. Most common
clinical presentation was claudication (74%) followed by, mus-
culoskeletal symptoms (48%), fatigue (46%), weight loss (22%),
headache (22%), visual disturbances (16%), syncope (10%), and
dyspnea (20%). Most common features were absent/diminished
pulses (80%), difference in blood pressure (80%), followed by
bruit (70%) hypertension (64%), cerebrovascular accident (8%),
heart failure (8%) and aortic regurgitation (4%). According to the
new angiographic classiﬁcation, angiographic type I (40%) was
encountered most frequently, followed by type III (30%), type V
(16%), type IIb (8%), type IIa (2%), and type IV was (4%). Angio-
plasty was the main stay of treatment in 66% of the patients,
remaining 34% of them were treated medically either with
corticosteroids or methotrexate.
Conclusion: Takayasu's arteritis is a rare disease, affects mainly
women, manifestations range from asymptomatic disease,
found as a result of impalpable pulses or bruits, to catastrophic
neurological impairment. TA is the common cause of renovas-
cular hypertension. Angiography remains the gold standard
for diagnosis. Angiographic evaluation and percutaneous
transluminal angioplasty with stenting is useful in selected
cases.
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Superior mesenteric artery ischemia is a rare condition with ser-
ious clinical consequences. It may be caused by either mechanical
or non mechanical obstruction of the artery. These patients
usually present with recurrent abdominal pain usually occurring
after meals. We report a 45-yr male patient presented with pain
abdomen and epigastric burning sensation, which increases with
food consumption since 6 months. Patient was evaluated and was
found to have severe erosive gastroduodenitis and was secondary
to superior mesenteric artery stenosis diagnosed on CT Abdomen.
Patient underwent successful SMA stenting. Repeat upper GI endo-
scopy during follow-up after 1 month showed complete resolution
of the duodenal mucosa and symptom free clinically.
Background: Superior mesenteric artery arises from abdominal
aorta distal to celiac trunk. Superior mesenteric artery ischemia
is a rare condition with serious clinical consequences. It may be
caused by either mechanical or non-mechanical obstruction of the
artery. Atherosclerotic mesenteric stenoses usually are focal and
most often located at the ostium or the proximal portion of these
vessels. These patients usually present with recurrent abdominal
pain usually occurring after meals. Therapeutic options include
surgical reconstruction and percutaneous transluminal angio-
plasty with or without stenting.
Case report: We report a case of 45-yr-old gentleman who came
with complaints of epigastric burning sensation and pain in upper
abdomen which increased after consumption of food since 6
months. He had consulted some clinics for his problem and was
advised antacids but was not relieved. He even underwent cardiac
evaluation for postprandial angina, which was normal. He was
subjected to upper GI endoscopy, which showed erosive gastro-
duodenitis. He was continued with antacids and proton pump
inhibitors. Since his symptoms continued to worsen, he consulted
a multispecialty hospital. He underwent repeat upper GI endo-
scopy, which showed worsening of the erosive Gastroduodenitis
(Fig. 1). The cause of which was suspected to be of ischemic origin.
He was subjected to CT Abdomen, which showed superior mesen-
teric artery occlusion (Fig. 2). He was referred to our institute for
further management. Through right femoral artery approach,
abdominal aortic angiogram was done which showed total occlu-
sion of SMA in its ostioproximal segment. A 6F selective SIM lateral
guiding catheter and pilot PTA guide wire was used. Lesion was
predilated followed by stenting with 7 mm  29 mm GENESIS per-
ipheral stent, which was deployed at 6 ATM (Fig. 3). Patient was
discharged on 3rd day in a stable state. On one-month follow-up,
he was asymptomatic and his upper GI endoscopy showed healing
of the mucosal erosions and also CT abdomen (Fig. 4) showed
patent stented segment. His 2 yrs follow-up with upper GI endo-
scopy showed normal gastroduodenal mucosa (Fig. 5).
Discussion: The superior mesenteric artery (SMA) arises from the
anterior surface of the abdominal aorta, 1 cm below the celiac
trunk and is at the lower border of the L1 vertebra in an adult. It
supplies the intestine from the lower part of the duodenum
through two-thirds of the transverse colon, aswell as the pancreas.
Mesenteric artery stenosis is a common ﬁnding in the elderly
patients with atherosclerotic disease, with a prevalence of 17.5%
in patients aged 65 yrs and above.1 Atherosclerotic mesenteric
stenosis usually are focal andmost often are located at the ostium
or ostioproximal segments of these vessels.2 Symptoms being
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recurrent, debilitating abdominal pain, usually occurring within
the ﬁrst hour after meals. Hence its been also referred to as
intestinal angina.3 This is due to insufﬁcient visceral blood ﬂow
during periods of heightened intestinal demands.4 Therapeutic
options include surgical reconstruction and percutaneous trans-
luminal angioplasty (PTA) with or without stent placement.5 PTA
has become an alternative to surgery in many high risk surgical
patients. The procedural and clinical success rate of PTA has been
reported to be greater than 80% and 75%, respectively.6–8 In PTA
without stenting, restenosis of the dilated artery and recurrence of
symptoms occur in 17–50% of patients within the ﬁrst year.6–8 This
reduces the efﬁcacy and durability of balloon angioplasty. Matsu-
moto et al. reported from his case series comparing PTA with and
without stenting, that PTAwith stentingwas associatedwith lower
incidence of complications and a higher technical and clinical
success rate.9 We report our patient who was initially diagnosed
as a case of acid peptic disease (APD) and later as postprandial
angina secondary to coronary ischemia. Our patient actually had
SMA stenosis and occlusion presenting as APD and postprandial
angina. Patient successfully underwent PTA with stenting with
dramatic improvement. His 2 yrs follow-up with upper GI endo-
scopy showed normal gastroduodenal mucosa.
Conclusion: SMA stenosis, a rare condition, presents as recurrent
abdominal pain with postprandial angina, should be carefully
considered because of its serious clinical consequences. PTA with
stenting has been considered as a safe and effective treatment
alternative to surgery.
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Introduction: Clopidrogel is the most common, cost effective med-
ication available for patients undergoing PCI. But variations in
CYP2C19 has been associated in decreasedmetabolism of this drug
leading to MACE. The other anti-platelet drugs considered in such
situations include Prasugrel and Ticagrelor, which are highly efﬁ-
cient when compared to Clopidrogel but are sometimes associated
with bleeding andTicagrelor is expensive. CYP2C19*2/*3 is themost
common, loss of function mutation in this gene, which reduces its
activity and hence lowmetabolism of Clopidrogel. Patients hetero-
zygous to anyone of these SNPs have to be put on alternative
treatment regime, which included Prasugrel and Ticagrelor or
higher doses of Clopidrogel.
Objective: To evaluate the efﬁciency of Clopidrogel (75 mg), Prasu-
grel (10 mg) and Ticagrelor (90 mg) in PCI patients heterozygous for
CYP2C19*2/*3.
Methodology: A total of 20 patients who have undergone PCI and
heterozygous for CYP2C19*2 and CYP2C19*3 variations were
recruited fromSri Balaji Hospital, Chrompet after obtainingwritten
informed consent. The patients were randomly categorized into 3
regimens: double dose Clopidrogel (75 mg), Prasugrel (10 mg), and
Ticagrelor (90 mg). Each group has 8, 8, and 4 patients, respectively.
The efﬁcacy of these drugs was evaluated by platelet response
array using FACS. Based on platelet reactivity index (PRI), theywere
classiﬁed as normal (<50), borderline, or poor (>50) response.
Results: Of the 8 patients who had Clopidrogel (75 mg), two had
borderline response and the rest 6 had poor response, and of
the 8 patients, who were on Prasugrel (10 mg), two had borderline
and 6 had good response. The 4 patients on Ticagrelor had good
response.
Conclusion: Evaluation of the efﬁcacy of these three anti-platelet
drugs in the heterozygous group of CYP2C19*2/*3 showed Ticagre-
lor is highly efﬁcient in preventing platelet aggregation followed by
Prasugrel in our cohort. Patients on double dose Clopidogrel have
high residual platelet reactivity.
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Back ground: Clopidogrel is an prodrug that requires hepatic
bioactivation by several enzymes including CYP2C19. Clopidogrel,
which is currently the mainstay of management after PCI, fails in
certain group of individuals, as they are unable to metabolize the
drug. Variations in the gene CYP2C19 has been associated with
poor metabolism of clopidogrel and hence mace
Methods: A total of 151 patients who have undergone PCI were
recruited from our institution after obtaining written informed
consent. Salivary samples from patients were genotyped for
CYP2C19*2, CYP2C19*3 variations by sequencing method (GAAP
X METHOD). Dual antiplatelets were given based on genotype
information.
Results: Based on their genotyping result for CYP2C19*2 and
CYP2C19*3, patients were categorized into 3 groups – normal
(GG,GG), intermediate (AG), and poor (homozygous variant AA).
Percentage of individuals in each group was 29, 52, and 19, respec-
tively. Poor metabolizers were given newer agents (Prasugrel or
Ticagrelor). Intermediate metabolizers were given newer agents or
double dose clopidogrel. Out of 151 patients followed-up for 6
months, only 3 patients (1.5%) were admitted with myocardial
infarction (troponin positive). They all underwent CAG – one
patient had stent thrombosis. He was not compliant with anti-
platelets. Other two had lesions in non-culprit vessels with patent
stents.
Conclusion: Major adverse coronary events after PCI were brought
down signiﬁcantly by genotyping individuals. Genotype may be
relevant for choosing appropriate dual antiplatelet therapy in
patients undergoing PCI.
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Absorb biodegradable biovascular scaffold (BVS) is a relatively new
device in themanagement of coronary artery disease. Initially, BVS
was studied in chronic stable lesions. There is emerging data on its
usage in acute coronary syndrome lesion. Themanufacturer advo-
cates 5 Ps during deployment of the scaffold (proper sizing, pre-
dilatation, pay attention to expansion limit, post dilation with
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